A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.



phosphosite cbn pc11 biopax bel_lc signor biogrid tas lincs_drug hprd trrust | geneways tees isi trips rlimsp medscan sparser reach

BRAF binds KRAS, NRAS, and PIK3CA. 4 / 4
| 4
"In this study, we aimed to investigate whether there is any correlation between the molecular profile and clinical outcome of pTNM stage I CRCs and whether mutations in KRAS , BRAF , NRAS , and PIK3CA genes are associated with histopathological features in this group of tumors."
"It was widely recognized that mutations in KRAS, BRAF, NRAS, and PIK3CA are significantly associated with a low response rate xref ."
"We optimized a 14-amplicon NGS panel to assess, in a consecutive cohort of 219 patients affected by mCRC, the presence and clinico-pathological associations of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes from formalin-fixed, paraffin-embedded specimens collected for diagnostics and research at the time of diagnosis."
"Of them, 36 patients did not exhibit mutations and 19 patients had one or more mutations: 16 patients had KRAS mutations (on exon 2: 14 patients and on exon 3-4: 2 patients), 1 NRAS mutation, 2 BRAF mutation and 4 PIK3CA mutations, associated with KRAS mutations in all of them (on exon 2: 3 patients and on exon 3-4: 1 patient)."